The multifaceted antitumor effects of the ALK5 inhibitor BI 4659 in colon cancer: an in vitro study of cytotoxicity, clonogenicity, migration, and 3D spheroid formation

Abstract

Purpose: Inhibition of ALK5, the main receptor of the TGF-β pathway, is one of the new strategies in colon cancer treatment. In this study, the anticancer effects of the small molecule BI 4659 were investigated in the colon cancer cell line Caco-2. Method: Caco-2 cells were treated with increasing doses of BI 4659 for 72 hours. WST-1 was used for the viability assay, colony formation was used to observe the long-term effect, wound healing was used to determine migration ability, and hanging drop assays were performed for 3D tumors. Findings: BI 4659 exhibited high cytotoxicity in a dose-dependent manner in the Caco-2 cell line (IC50 = 29.33 ± 2.35 nM). Treatment resulted in significantly reduced colony formation, migration ability, and 3D spheroid size (p <0.05). Conclusion: Treatment with BI 4659 produced a multifaceted antitumor effect in the Caco-2 cell line. Inhibition of ALK5 showed an inhibitory effect on proliferation, migration, and 3D organization. These results suggest that BI 4659 may be a potential candidate for colon cancer treatment. Further experiments are recommended to elucidate the underlying molecular mechanisms and demonstrate vivo effects.

Keywords

• colon cancer
• ALK5 inhibitor
• BI 4659
• TGF-β
• cell migration
• tumor sprehoids

Supporting Institution

No Funding Received

Ethical Statement

This study does not require ethical approval

Thanks

I would like to thank the staff of Bingöl University Cancer Research Laboratory for their technical assistance and valuable support during this study.

Kolon kanserinde ALK5 inhibitörü BI 4659'un çok yönlü antitümör etkileri: sitotoksisite, klonojeniklik, göç ve 3D sferoid oluşumu üzerine bir in vitro çalışma

Abstract

Amaç: TGF- β yolunun ana reseptörü olan ALK5’in inhibe edilmesi, kolon kanseri tedavsinde yeni stratejilerden birisidir. Bu çalışmada kolon kanser hücre hattı Caco-2’de küçük moleküllü BI 4659’un antikanser etkileri incelendi. Metod: Caco-2 hücreleri artan dozlarda BI 4659 ile 72 saat süre ile tedavi edildi. Canlılık deneyi için WST-1, uzun süreli etkiyi görmek için koloni formasyon, migrasyon yeteneğini belirlemek için Wound healing, 3B tümör için ise hanging drop deneyleri yapıldı. Bulgular: BI 4659, Caco-2 hücre hattında doza bağlı olarak yüksek sitotoksisite gösterdi (IC50 = 29.33 ± 2.35 nM). Tedavi ile koloni oluşumu, migrasyon yeteneği ve 3B sferoit büyüklüğü anlamlı düzeyde düşük çıktı (p <0.05). Sonuç: BI 4659 tedavisiyle Caco-2 hücre hattında çok yönlü antitümör etki ortaya çıkmıştır. ALK5’in inhibisyonu proliferasyon, göç ve 3B organizasyonunda baskılayıcı etki göstermiştir. Bu sonuçlar kolon kanseri tedavisinde BI 4659’un potansiyel bir aday olabileceğini göstermektedir. Altta yatan moleküler mekanizmaların ve in vivo etkilerin gösterilmesi için ileri deneylerin yapılması tavsiye edilmektedir.

Keywords

• kolon kanseri
• ALK5 inhibitörü
• BI 4659
• TGF-β
• hücre göçü
• tümör sferoidleri

Supporting Institution

Destekleyen kuruluş yok.

Ethical Statement

Bu çalışmada etik izin gerekli değildir.

Thanks

Bu çalışma sırasında teknik yardımları ve değerli destekleri için Bingöl Üniversitesi Kanser Araştırma Laboratuvarı çalışanlarına teşekkür ederim.

References

1. [1] İzgördü, H., Selvi, O., & Kutlu, H. M. (2025). Modulation of sphingolipid metabolism: Investigation of the apoptotic and cytotoxic effects of the ceramidase inhibitor De-MAPP in HT29 colon cancer cells. Biological Diversity and Conservation, 18(3), 283–290. https://doi.org/10.46309/biodicon.2025.1604413
2. [2] Klimeck, L., Heisser, T., Hoffmeister, M., & Brenner, H. (2023). Colorectal cancer: A health and economic problem. Best Practice & Research Clinical Gastroenterology, 66, 101839. https://doi.org/10.1016/j.bpg.2023.101839
3. [3] Üstüner, D., Güneş, S., Sarıboyacı, A. E., Uysal, O., Sevimli, T. S., & Soykan, M. N. (2022). Rekombinant klotho proteininin insan kolorektal kanser hücreleri üzerindeki apoptotik etkilerinin değerlendirilmesi. Biological Diversity and Conservation, 15(2), 134–142. https://doi.org/10.46309/biodicon.2022.1105789
4. [4] Chai, Y., Liu, J. L., Zhang, S., Li, N., Xu, D. Q., & Liu, W. J. (2024). The effective combination therapies with irinotecan for colorectal cancer. Frontiers in Pharmacology, 15, 1356708. https://doi.org/10.3389/fphar.2024.1356708 [5] Gollner, A., Heine, C., & Hofbauer, K. S. (2023). Kinase degraders, activators, and inhibitors: Highlights and synthesis routes to the chemical probes on opnMe.com, Part 1. ChemMedChem, 18(10). https://doi.org/10.1002/cmdc.202300031
5. [6] Mansour, M. A., Hassan, G. S., Serya, R. A. T., Jaballah, M. Y., & Abouzid, K. A. M. (2024). Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors. Bioorganic Chemistry, 147, 107332. https://doi.org/10.1016/j.bioorg.2024.107332
6. [7] Zhang, Z., Qiao, Y., Yang, L., Chen, Z., Li, T., Gu, M., et al. (2021). Kaempferol 3-O-gentiobioside, an ALK5 inhibitor, affects the proliferation, migration, and invasion of tumor cells via blockade of the TGF-β/ALK5/Smad signaling pathway. Phytotherapy Research, 35(11), 6310–6323. https://doi.org/10.1002/ptr.7278
7. [8] Baldwin, R. L., Friess, H., Yokoyama, M., Lopez, M. E., Kobrin, M. S., & Büchler, M. W. (1996). Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition. International Journal of Cancer, 67(2), 283–288. https://doi.org/10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC17>3.0.CO;2-6
8. [9] Park, C. Y., Son, J. Y., Jin, C. H., Nam, J. S., Kim, D. K., & Sheen, Y. Y. (2011). EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. European Journal of Cancer, 47(17), 2642–2653. doi:10.1016/j.ejca.2011.06.038

9. [10] Boehringer Ingelheim. (2017). opnMe.com - Boehringer Ingelheim Open Innovation Portal.
10. [11] Hanke, T., Wong, J. F., Berger, B. T., Abdi, I., Berger, L. M., Tesch, R., et al. (2020). A highly selective chemical probe for activin receptor-like kinases ALK4 and ALK5. ACS Chemical Biology, 15(4), 862–870. https://doi.org/ 10.1021/acschembio.0c00076
11. [12] Erdoğan, M. K. (2021). The chemosensitizing effect of Portulaca oleracea methanol extract on human colorectal and lung cancer cells against irinotecan. KSÜ Tarım ve Doğa Dergisi, 24(6), 1187–1195. https://doi:10.18016/ksutarimdoga.vi.848187
12. [13] Sever, A., Erdoğan, M. K., Gündoğdu, R., Geçibesler, İ. H., & Behçet, L. (2025). Evaluation of the anticancer potential of S. euphratica, S. staminea, and S. trichoclada in colon cancer. Journal of Medical Sciences, 94(4), e1469. https://doi.org/ 10.20883/medical.e1469
13. [14] Khodavirdipour, A., Zarean, R., & Safaralizadeh, R. (2021). Evaluation of the anti-cancer effect of Syzygium cumini ethanolic extract on HT-29 colorectal cell line. Journal of Gastrointestinal Cancer, 52, 575–581. https://doi.org/10.1007/s12029-020-00439-3
14. [15] Rasouli, M., Safari, F., Kanani, M. H., & Ahvati, H. (2024). Principles of hanging drop method (spheroid formation) in cell culture. In Autophagy in Development and Disease. Springer. https://doi.org/ 10.1007/7651_2024_527
15. [16] Foty, R. (2011). A simple hanging drop cell culture protocol for generation of 3D spheroids. Journal of Visualized Experiments, 51, e2720. https://doi.org/10.3791/2720
16. [17] Macrae, F. A. (2016). Colorectal cancer: Epidemiology, risk factors, and protective factors. In UpToDate. Retrieved April 5, 2026, from https://www.uptodate.com
17. [18] Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015). Targeting cancer with kinase inhibitors. Journal of Clinical Investigation, 125(5), 1780–1789. https://doi.org/10.1172/JCI76094
18. [19] Guo, F. Y., Li, S., Zhang, C., & Jin, C. H. (2025). ALK5 kinase inhibitors in drug discovery: Structural insights and therapeutic applications. European Journal of Medicinal Chemistry, 299, 118045. https://doi.org/10.1016/j.ejmech.2025.118045
19. [20] Teicher, B. A. (2021). TGFβ-directed therapeutics: 2020. Pharmacology & Therapeutics, 217, 107666. https://doi.org/10.1016/j.pharmthera.2020.107666
20. [21] Arai, M., Hanada, M., Taniguchi, H., Nakajima, F., Ohmoto, H., & Inoue, T. (2025). Discovery of HM-279, a potent inhibitor of ALK5 for improving therapeutic efficacy of cancer immunotherapy. Journal of Medicinal Chemistry, 68(7), 7106–7118. https://doi.org/10.1021/acs.jmedchem.4c02293
21. [22] Boldbaatar, A., Lee, S., Han, S., Jeong, A. L., Ka, H. I., & Buyanravjikh, S. (2017). Eupatolide inhibits the TGF-β1-induced migration of breast cancer cells. Oncology Letters, 14(5), 6031–6039. https://doi.org/ 10.3892/ol.2017.6957
22. [23] Bonomo, S., Giovannoni, R., Lavitrano, M., Cadamuro, M., & Conconi, D. (2025). TGF-β receptor inhibitor SB431542 enhanced the sensitivity of gastric cancer to 5-fluorouracil. International Journal of Molecular Sciences, 26(23), 11250. https://doi.org/10.3390/ijms262311250
23. [24] Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gunduz, N., Gentaz, P., & Cammareri, P. (2022). Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis. Nature Communications, 13, 7551. https://doi.org/ 10.1038/s41467-022-35134-3
24. [25] Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., & Ao, H. (2020). The roles of cyclin-dependent kinases in cell-cycle progression. International Journal of Molecular Sciences, 21(6), 1960. https://doi.org/10.3390/ijms21061960